Cargando…
Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer
Significance: Photodynamic therapy (PDT) could become a treatment option for nonmuscle invasive bladder cancer when the current high morbidity rate associated with red light PDT and variable PDT dose can be overcome through a combination of intravesical instillation of the photosensitizer and the us...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society of Photo-Optical Instrumentation Engineers
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289452/ https://www.ncbi.nlm.nih.gov/pubmed/32529817 http://dx.doi.org/10.1117/1.JBO.25.6.068001 |
_version_ | 1783545467107278848 |
---|---|
author | Lilge, Lothar Wu, Jenny Xu, Yiwen Manalac, Angelica Molenhuis, Daniel Schwiegelshohn, Fynn Vesselov, Leonid Embree, Wayne Nesbit, Michael Betz, Vaughn Mandel, Arkady Jewett, Michael A. S. Kulkarni, Girish S. |
author_facet | Lilge, Lothar Wu, Jenny Xu, Yiwen Manalac, Angelica Molenhuis, Daniel Schwiegelshohn, Fynn Vesselov, Leonid Embree, Wayne Nesbit, Michael Betz, Vaughn Mandel, Arkady Jewett, Michael A. S. Kulkarni, Girish S. |
author_sort | Lilge, Lothar |
collection | PubMed |
description | Significance: Photodynamic therapy (PDT) could become a treatment option for nonmuscle invasive bladder cancer when the current high morbidity rate associated with red light PDT and variable PDT dose can be overcome through a combination of intravesical instillation of the photosensitizer and the use of green light creating a steep PDT dose gradient. Aim: To determine how a high PDT selectivity can be maintained throughout the bladder wall considering other efficacy determining parameters, in particular, the average optical properties of the mucosal layer governing the fluence rate multiplication factor, as well as the bladder shape and the position of the emitter in relationship to the bladder wall. Approach: We present three irradiance monitoring systems and evaluate their ability to enable selective bladder PDT considering previously determined photodynamic threshold values for the bladder cancer, mucosa and urothelium in a preclinical model, and the photosensitizer’s specific uptake ratio. Monte Carlo-based light propagation simulations performed for six human bladders at the time of therapy for a range of tissue optical properties. The performance of one irradiance sensing device in a clinical phase 1B trial is presented to underline the impact of irradiance monitoring, and it is compared to the Monte Carlo-derived dose surface histogram. Results: Monte Carlo simulations showed that irradiance monitoring systems need to comprise at least three sensors. Light scattering inside the bladder void needs to be minimized to prevent increased heterogeneity of the irradiance. The dose surface histograms vary significantly depending on the bladder shape and bladder volume but are less dependent on tissue optical properties. Conclusions: We demonstrate the need for adequate irradiance monitoring independent of a photosensitizer’s specific uptake ratio. |
format | Online Article Text |
id | pubmed-7289452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Society of Photo-Optical Instrumentation Engineers |
record_format | MEDLINE/PubMed |
spelling | pubmed-72894522020-06-17 Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer Lilge, Lothar Wu, Jenny Xu, Yiwen Manalac, Angelica Molenhuis, Daniel Schwiegelshohn, Fynn Vesselov, Leonid Embree, Wayne Nesbit, Michael Betz, Vaughn Mandel, Arkady Jewett, Michael A. S. Kulkarni, Girish S. J Biomed Opt Therapeutic Significance: Photodynamic therapy (PDT) could become a treatment option for nonmuscle invasive bladder cancer when the current high morbidity rate associated with red light PDT and variable PDT dose can be overcome through a combination of intravesical instillation of the photosensitizer and the use of green light creating a steep PDT dose gradient. Aim: To determine how a high PDT selectivity can be maintained throughout the bladder wall considering other efficacy determining parameters, in particular, the average optical properties of the mucosal layer governing the fluence rate multiplication factor, as well as the bladder shape and the position of the emitter in relationship to the bladder wall. Approach: We present three irradiance monitoring systems and evaluate their ability to enable selective bladder PDT considering previously determined photodynamic threshold values for the bladder cancer, mucosa and urothelium in a preclinical model, and the photosensitizer’s specific uptake ratio. Monte Carlo-based light propagation simulations performed for six human bladders at the time of therapy for a range of tissue optical properties. The performance of one irradiance sensing device in a clinical phase 1B trial is presented to underline the impact of irradiance monitoring, and it is compared to the Monte Carlo-derived dose surface histogram. Results: Monte Carlo simulations showed that irradiance monitoring systems need to comprise at least three sensors. Light scattering inside the bladder void needs to be minimized to prevent increased heterogeneity of the irradiance. The dose surface histograms vary significantly depending on the bladder shape and bladder volume but are less dependent on tissue optical properties. Conclusions: We demonstrate the need for adequate irradiance monitoring independent of a photosensitizer’s specific uptake ratio. Society of Photo-Optical Instrumentation Engineers 2020-06-11 2020-06 /pmc/articles/PMC7289452/ /pubmed/32529817 http://dx.doi.org/10.1117/1.JBO.25.6.068001 Text en © 2020 The Authors https://creativecommons.org/licenses/by/4.0/ Published by SPIE under a Creative Commons Attribution 4.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. |
spellingShingle | Therapeutic Lilge, Lothar Wu, Jenny Xu, Yiwen Manalac, Angelica Molenhuis, Daniel Schwiegelshohn, Fynn Vesselov, Leonid Embree, Wayne Nesbit, Michael Betz, Vaughn Mandel, Arkady Jewett, Michael A. S. Kulkarni, Girish S. Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer |
title | Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer |
title_full | Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer |
title_fullStr | Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer |
title_full_unstemmed | Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer |
title_short | Minimal required PDT light dosimetry for nonmuscle invasive bladder cancer |
title_sort | minimal required pdt light dosimetry for nonmuscle invasive bladder cancer |
topic | Therapeutic |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289452/ https://www.ncbi.nlm.nih.gov/pubmed/32529817 http://dx.doi.org/10.1117/1.JBO.25.6.068001 |
work_keys_str_mv | AT lilgelothar minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT wujenny minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT xuyiwen minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT manalacangelica minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT molenhuisdaniel minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT schwiegelshohnfynn minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT vesselovleonid minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT embreewayne minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT nesbitmichael minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT betzvaughn minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT mandelarkady minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT jewettmichaelas minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer AT kulkarnigirishs minimalrequiredpdtlightdosimetryfornonmuscleinvasivebladdercancer |